Neuland Laboratories Limited (BOM: 524558)
India
· Delayed Price · Currency is INR 13,196
-630 (-4.56%)
At close: Jan 21, 2025
Neuland Laboratories Revenue
Neuland Laboratories had revenue of 3.11B INR in the quarter ending September 30, 2024, a decrease of -25.59%. This brings the company's revenue in the last twelve months to 15.28B, up 4.87% year-over-year. In the fiscal year ending March 31, 2024, Neuland Laboratories had annual revenue of 15.59B with 30.81% growth.
Revenue (ttm)
15.28B
Revenue Growth
+4.87%
P/S Ratio
11.08
Revenue / Employee
9.30M
Employees
1,643
Market Cap
169.30B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Mar 31, 2024 | 15.59B | 3.67B | 30.81% |
| Mar 31, 2023 | 11.91B | 2.40B | 25.20% |
| Mar 31, 2022 | 9.52B | 147.07M | 1.57% |
| Mar 31, 2021 | 9.37B | 1.73B | 22.64% |
| Mar 31, 2020 | 7.64B | 965.74M | 14.47% |
| Mar 31, 2019 | Pro | Pro | Pro |
| Mar 31, 2018 | Pro | Pro | Pro |
| Mar 31, 2017 | Pro | Pro | Pro |
| Mar 31, 2016 | Pro | Pro | Pro |
| Mar 31, 2015 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Reliance Industries | 9,398.38B |
| Tata Consultancy Services | 2,520.82B |
| HDFC Bank | 2,761.06B |
| Bharti Airtel | 1,554.78B |
| ICICI Bank | 1,638.51B |
| Infosys | 1,635.60B |
| State Bank of India | 3,360.28B |
| Hindustan Unilever | 624.10B |
Neuland Laboratories News
- 5 weeks ago - Mixed trends in November CDRMO exports, prefer Syngene and Neuland Labs over Divis Labs and Laurus Labs - Business Upturn
- 5 weeks ago - Neuland Labs exports surge threefold YoY in November, 43.1% MoM growth - Business Upturn
- 5 weeks ago - Neuland Labs shares down over 5% as 4.8 lakh shares worth Rs 747 crore change hands in block trade - Business Upturn
- 2 months ago - Neuland Laboratories shares surge nearly 10% amid AbbVie’s phase 2 setback on schizophrenia drug - Business Upturn
- 2 months ago - Goldman Sachs maintains buy on Neuland Labs, raises target to Rs 15,250; sees 7% upside potential - Business Upturn
- 2 months ago - Neuland Laboratories shares plunge over 13% after disappointing Q2 FY25 results; revenue down 25.1% YoY to ₹315.2 crore, PAT declines 64.1% - Business Upturn
- 2 months ago - Neuland Laboratories Q2 FY25 Results: Revenue down 25.1% YoY to ₹315.2 crore, PAT declines 64.1% - Business Upturn
- 3 months ago - Stocks to Buy This Diwali: AngelOne sees Neuland Laboratories reaching ₹19,580, with 25% growth potential - Business Upturn